Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus KANTREX.
BACITRACIN-NEOMYCIN-POLYMYXIN vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Apply topically to affected area 2-5 times daily.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic